Edition:
United Kingdom

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

0.29USD
24 May 2019
Change (% chg)

$0.01 (+3.40%)
Prev Close
$0.28
Open
$0.27
Day's High
$0.34
Day's Low
$0.27
Volume
368,867
Avg. Vol
165,740
52-wk High
$2.99
52-wk Low
$0.22

Latest Key Developments (Source: Significant Developments)

Cytori Q1 Loss Per Share $0.18
Tuesday, 14 May 2019 

May 14 (Reuters) - Cytori Therapeutics Inc ::CYTORI REPORTS Q1 2019 BUSINESS AND FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.18.ENDED Q1 WITH APPROXIMATELY $3.9 MILLION OF CASH AND CASH EQUIVALENTS..Q1 2019 PRODUCT REVENUES WERE $0.7 MILLION, COMPARED TO $0.7 MILLION FOR Q1 2018.  Full Article

Cytori Therapeutics Says Gary Titus Appointed CFO
Monday, 18 Mar 2019 

March 18 (Reuters) - Cytori Therapeutics Inc ::SAYS GARY TITUS APPOINTED CFO.ON MARCH 15 TIAGO GIRAO NOTIFIED CO OF HIS INTENTION TO RESIGN AS CFO - SEC FILING.  Full Article

Cytori Therapeutics Q3 Adjusted Loss Per Share $0.45
Wednesday, 14 Nov 2018 

Cytori Therapeutics Inc ::CYTORI REPORTS Q3 2018 BUSINESS AND FINANCIAL RESULTS.Q3 ADJUSTED LOSS PER SHARE $0.45.Q3 LOSS PER SHARE $0.55.  Full Article

Cytori Therapeutics Says Cancer Treatment Receives FDA Orphan Drug Designation
Monday, 17 Sep 2018 

Sept 17 (Reuters) - Cytori Therapeutics Inc ::PHASE 2 READY ONCOLOGY DRUG RECEIVES FDA ORPHAN DRUG DESIGNATION.CYTORI THERAPEUTICS INC - RECEIVED FDA ORPHAN DRUG DESIGNATION FOR ITS ATI-1123 CHEMOTHERAPY DRUG PRODUCT CANDIDATE.  Full Article

Cytori Therapeutics - Entered Second Amendment To Its Existing Loan And Security Agreement
Wednesday, 20 Jun 2018 

June 20 (Reuters) - Cytori Therapeutics Inc ::CYTORI THERAPEUTICS INC - ON JUNE 19, ENTERED SECOND AMENDMENT TO ITS EXISTING LOAN AND SECURITY AGREEMENT, DATED MAY 29, 2015- SEC FILING.CYTORI THERAPEUTICS INC - THE SECOND AMENDMENT EXTENDS INTEREST-ONLY PERIOD UNDER LOAN AGREEMENT TO AUGUST 1, 2018.  Full Article

Cytori Provides Update On U.S. Manufacturing And EU Approval Plans For ATI-0918, Liposomal Doxorubicin
Monday, 30 Apr 2018 

April 30 (Reuters) - Cytori Therapeutics Inc ::CYTORI PROVIDES UPDATE ON U.S. MANUFACTURING AND EU APPROVAL PLANS FOR ATI-0918, LIPOSOMAL DOXORUBICIN.CYTORI THERAPEUTICS - INTENDS TO FIRST SEEK EUROPEAN APPROVAL FOR ITS DRUG, APPLIED FOR, GOT EMA APPROVAL TO FILE FOR CENTRALIZED EU APPROVAL.  Full Article

Cytori Q4 Adjusted Loss Per Share $0.10
Thursday, 8 Mar 2018 

March 8 (Reuters) - Cytori Therapeutics Inc ::CYTORI REPORTS FOURTH QUARTER AND FULL YEAR 2017 BUSINESS AND FINANCIAL RESULTS.Q4 ADJUSTED LOSS PER SHARE $0.10.Q4 LOSS PER SHARE $0.20.Q4 EARNINGS PER SHARE VIEW $-0.09 -- THOMSON REUTERS I/B/E/S.  Full Article

Swissquote Bank SA Reports 12 pct Passive Stake In Cytori Therapeutics As Of Dec. 29, 2017
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Cytori Therapeutics Inc ::SWISSQUOTE BANK SA REPORTS 12 PERCENT PASSIVE STAKE IN CYTORI THERAPEUTICS INC AS OF DECEMBER 29, 2017 - SEC FILING‍​.  Full Article

Cytori Therapeutics Inc ‍announces new investigator initiated U.S. clinical trial for hip osteonecrosis​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Cytori Therapeutics Inc :Cytori Therapeutics Inc - ‍announced a new investigator initiated U.S. clinical trial for hip osteonecrosis​.  Full Article

Cytori reports Q3 loss per share $0.14
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Cytori Therapeutics Inc :Cytori reports third quarter 2017 business and financial results.Q3 loss per share $0.14.Cytori Therapeutics Inc - ‍received U.S. FDA IDE approval for relief, a thermal burn pilot trial related to ongoing barda contract​.Cytori Therapeutics Inc - ‍expects full year 2017 operating cash burn to be lower than 2016, primarily due to restructuring announced in September 2017​.  Full Article